



REGISTER NOW

THERAKOS WEBINAR

Immunomodulation in acute GvHD: a fit for ECP?

 | Professor Amin Alousi  | Oct 14th 2021  | 6pm – 7pm (CET)

CLICK HERE TO REGISTER NOW

GvHD: graft-versus-host-disease; ECP: extracorporeal photopheresis.

This information is not intended for healthcare professionals based in the US and Canada



Professor Amin Alousi

Professor of Medicine in the Department of Stem Cell Transplant and Cellular Therapy at the University of Texas, MD Anderson Cancer Center.

His area of research is in the prevention and treatment of acute and chronic GvHD as well as survivorship needs in recipients of allogeneic hematopoietic cell transplantation.

This is an educational programme run by Therakos (UK) Ltd, a Mallinckrodt Company

To find out more visit our [website](#) and [follow us](#) on 

*Although we have determined that we have a legitimate interest in using your data for marketing and sales purposes as per the terms of the current data protection legislation, you can opt-out by replying to this mail indicating “unsubscribe” in the email body. Our **Privacy Notice** provides additional information.*

Mallinckrodt, the “M” brand mark and the Mallinckrodt Pharmaceuticals logo are trademarks of a Mallinckrodt company. Other brands are trademarks of a Mallinckrodt company or their respective owners © 2021 Mallinckrodt.

Item code: EU-2100209. Date of preparation: September 2021